Pharmacokinetic studies in infants using minimal-risk study designs

Area of Science:

• Pediatric Pharmacology
• Clinical Drug Development
• Pharmacokinetics in Infants

Background:

• Infants are considered 'therapeutic orphans' due to limited drug data.
• Off-label drug use in infants increases risks of toxicity and suboptimal efficacy.
• Challenges in infant clinical trials create a knowledge gap in pediatric pharmacology.

Purpose of the Study:

• To review minimal-risk approaches for characterizing drug pharmacokinetics in infants.
• To identify efficient and suitable study designs for pediatric drug evaluation.
• To address the need for better pharmacokinetic data in vulnerable infant populations.

Main Methods:

• Critical review of existing literature on minimal-risk pharmacokinetic studies in infants.
• Evaluation of established methods like population pharmacokinetic (PK) analysis with sparse sampling.
• Assessment of emerging strategies including dried blood spots, opportunistic designs, and non-blood matrices.

Main Results:

• Population PK with sparse sampling is a well-established method.
• Dried blood spots, opportunistic sampling, and non-blood matrices are promising, increasingly used alternatives.
• Physiologically based pharmacokinetic modeling offers insights but requires further prospective validation.

Conclusions:

• Minimal-risk approaches are crucial for advancing pediatric drug knowledge.
• Continued experience with novel methods will refine study designs for infant pharmacokinetics.
• Improved pharmacokinetic understanding will enhance drug safety and efficacy in infants.